Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis

M. Beccaria, M. Luisetti, G. Rodi, A. Corsico, M. C. Zoia, S. Colato, P. Pochetti, A. Braschi, E. Pozzi, I. Cerveri

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Whole lung lavage (WLL) is still the gold-standard therapy for pulmonary alveolar proteinosis (PAP). The few studies on the duration of the effect of WLL, belonging to a rather remote period, show significant but transient benefits. In 21 patients with idiopathic PAP, the duration of any benefit and, in 16 of them, the time course of lung function improvement (at baseline, 1 week, 6 months, 1 yr and then every 2 yrs after WLL) were evaluated. The present WLL technique takes longer, is invasively monitored and partially modified with respect to past techniques. More than 70%, of patients remained free from recurrent PAP at 7 yrs. The bulk of the improvement in spirometric results was almost completely gained in the immediate post-WLL period due to the efficient clearance of the alveoli. At a median of 5 yrs, recovery of diffusing capacity of the lung for carbon monoxide was incomplete (75±19% of the predicted value) and there were residual gas exchange abnormalities (alveolar to arterial oxygen tension difference 3.6±1.5 kPa (27±11 mmHg ) and exercise limitation, probably explained by engorgement of lymphatic vessels. In conclusion, whole lung lavage for idiopathic pulmonary alveolar proteinosis is currently a safe procedure in an experienced setting, and provides long-lasting benefits in the majority of patients.

Original languageEnglish
Pages (from-to)526-531
Number of pages6
JournalEuropean Respiratory Journal
Volume23
Issue number4
DOIs
Publication statusPublished - Apr 2004

Fingerprint

Pulmonary Alveolar Proteinosis
Bronchoalveolar Lavage
Lung Volume Measurements
Lymphatic Vessels
Carbon Monoxide
Gold
Arterial Pressure
Gases
Exercise
Oxygen
Lung

Keywords

  • Bronchoalveolar lavage
  • Follow-up studies
  • Pulmonary alveolar proteinosis
  • Respiratory function tests

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. / Beccaria, M.; Luisetti, M.; Rodi, G.; Corsico, A.; Zoia, M. C.; Colato, S.; Pochetti, P.; Braschi, A.; Pozzi, E.; Cerveri, I.

In: European Respiratory Journal, Vol. 23, No. 4, 04.2004, p. 526-531.

Research output: Contribution to journalArticle

Beccaria, M. ; Luisetti, M. ; Rodi, G. ; Corsico, A. ; Zoia, M. C. ; Colato, S. ; Pochetti, P. ; Braschi, A. ; Pozzi, E. ; Cerveri, I. / Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. In: European Respiratory Journal. 2004 ; Vol. 23, No. 4. pp. 526-531.
@article{a5e9fd1670e84fb790401f455197f319,
title = "Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis",
abstract = "Whole lung lavage (WLL) is still the gold-standard therapy for pulmonary alveolar proteinosis (PAP). The few studies on the duration of the effect of WLL, belonging to a rather remote period, show significant but transient benefits. In 21 patients with idiopathic PAP, the duration of any benefit and, in 16 of them, the time course of lung function improvement (at baseline, 1 week, 6 months, 1 yr and then every 2 yrs after WLL) were evaluated. The present WLL technique takes longer, is invasively monitored and partially modified with respect to past techniques. More than 70{\%}, of patients remained free from recurrent PAP at 7 yrs. The bulk of the improvement in spirometric results was almost completely gained in the immediate post-WLL period due to the efficient clearance of the alveoli. At a median of 5 yrs, recovery of diffusing capacity of the lung for carbon monoxide was incomplete (75±19{\%} of the predicted value) and there were residual gas exchange abnormalities (alveolar to arterial oxygen tension difference 3.6±1.5 kPa (27±11 mmHg ) and exercise limitation, probably explained by engorgement of lymphatic vessels. In conclusion, whole lung lavage for idiopathic pulmonary alveolar proteinosis is currently a safe procedure in an experienced setting, and provides long-lasting benefits in the majority of patients.",
keywords = "Bronchoalveolar lavage, Follow-up studies, Pulmonary alveolar proteinosis, Respiratory function tests",
author = "M. Beccaria and M. Luisetti and G. Rodi and A. Corsico and Zoia, {M. C.} and S. Colato and P. Pochetti and A. Braschi and E. Pozzi and I. Cerveri",
year = "2004",
month = "4",
doi = "10.1183/09031936.04.00102704",
language = "English",
volume = "23",
pages = "526--531",
journal = "European Journal of Respiratory Diseases",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "4",

}

TY - JOUR

T1 - Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis

AU - Beccaria, M.

AU - Luisetti, M.

AU - Rodi, G.

AU - Corsico, A.

AU - Zoia, M. C.

AU - Colato, S.

AU - Pochetti, P.

AU - Braschi, A.

AU - Pozzi, E.

AU - Cerveri, I.

PY - 2004/4

Y1 - 2004/4

N2 - Whole lung lavage (WLL) is still the gold-standard therapy for pulmonary alveolar proteinosis (PAP). The few studies on the duration of the effect of WLL, belonging to a rather remote period, show significant but transient benefits. In 21 patients with idiopathic PAP, the duration of any benefit and, in 16 of them, the time course of lung function improvement (at baseline, 1 week, 6 months, 1 yr and then every 2 yrs after WLL) were evaluated. The present WLL technique takes longer, is invasively monitored and partially modified with respect to past techniques. More than 70%, of patients remained free from recurrent PAP at 7 yrs. The bulk of the improvement in spirometric results was almost completely gained in the immediate post-WLL period due to the efficient clearance of the alveoli. At a median of 5 yrs, recovery of diffusing capacity of the lung for carbon monoxide was incomplete (75±19% of the predicted value) and there were residual gas exchange abnormalities (alveolar to arterial oxygen tension difference 3.6±1.5 kPa (27±11 mmHg ) and exercise limitation, probably explained by engorgement of lymphatic vessels. In conclusion, whole lung lavage for idiopathic pulmonary alveolar proteinosis is currently a safe procedure in an experienced setting, and provides long-lasting benefits in the majority of patients.

AB - Whole lung lavage (WLL) is still the gold-standard therapy for pulmonary alveolar proteinosis (PAP). The few studies on the duration of the effect of WLL, belonging to a rather remote period, show significant but transient benefits. In 21 patients with idiopathic PAP, the duration of any benefit and, in 16 of them, the time course of lung function improvement (at baseline, 1 week, 6 months, 1 yr and then every 2 yrs after WLL) were evaluated. The present WLL technique takes longer, is invasively monitored and partially modified with respect to past techniques. More than 70%, of patients remained free from recurrent PAP at 7 yrs. The bulk of the improvement in spirometric results was almost completely gained in the immediate post-WLL period due to the efficient clearance of the alveoli. At a median of 5 yrs, recovery of diffusing capacity of the lung for carbon monoxide was incomplete (75±19% of the predicted value) and there were residual gas exchange abnormalities (alveolar to arterial oxygen tension difference 3.6±1.5 kPa (27±11 mmHg ) and exercise limitation, probably explained by engorgement of lymphatic vessels. In conclusion, whole lung lavage for idiopathic pulmonary alveolar proteinosis is currently a safe procedure in an experienced setting, and provides long-lasting benefits in the majority of patients.

KW - Bronchoalveolar lavage

KW - Follow-up studies

KW - Pulmonary alveolar proteinosis

KW - Respiratory function tests

UR - http://www.scopus.com/inward/record.url?scp=11144354913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11144354913&partnerID=8YFLogxK

U2 - 10.1183/09031936.04.00102704

DO - 10.1183/09031936.04.00102704

M3 - Article

VL - 23

SP - 526

EP - 531

JO - European Journal of Respiratory Diseases

JF - European Journal of Respiratory Diseases

SN - 0903-1936

IS - 4

ER -